SI vs UFPT
SI: Shoulder Innovations develops orthopedic devices for shoulder and upper extremity conditions, showing explosive revenue growth but facing profitability challenges and dramatic stock depreciation. UFPT: A specialized contract manufacturer producing custom single-use and single-patient medical devices for major OEMs across minimally invasive surgery, wound care, orthopedics, and biopharma applications.
Side-by-side fundamentals
| Metric | SI | UFPT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $20.31 | $237.96 | |
| Market cap as of 2026-07-23 | $421M | $1.9B | |
| P/E as of 2026-07-23 | n/a | 27.03 | |
| PEG as of 2026-07-23 | -0.06 | 3.50 | SI lower |
| Net margin as of 2026-07-23 | -17.1% | +11.3% | UFPT higher |
| Gross margin as of 2026-07-23 | +77.0% | +28.4% | SI higher |
| Operating margin as of 2026-07-23 | -55.4% | +15.2% | UFPT higher |
| ROE as of 2026-07-23 | -13.6% | +16.6% | UFPT higher |
| ROA as of 2026-07-23 | -10.9% | +10.5% | UFPT higher |
| Debt / equity as of 2026-07-23 | 0.11 | 0.31 | SI lower |
| Revenue growth (YoY) as of 2026-07-23 | +151.0% | +11.2% | SI higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +22.7% | |
| Beta as of 2026-07-23 | 14.87 | 1.07 | |
| 1-year return as of 2026-07-22 close | -98.9% | +3.0% | UFPT higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.